Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
$2.19
-5.6%
$2.88
$3.25
$17.50
$1.69M1.091,859 shs22,628 shs
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$6.90
+2.7%
$4.99
$1.86
$9.01
$17.87M1.0367,011 shs28,099 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$3.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
International Stem Cell Co. stock logo
ISCO
International Stem Cell
$0.07
-13.3%
$0.09
$0.05
$0.17
$520K0.521,188 shs1,566 shs
Teligent, Inc. stock logo
TLGT
Teligent
$0.03
$0.17
$1.60
N/AN/AN/A6,460 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
+5.45%+1.75%-7.94%-40.97%-67.51%
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
-2.04%+40.00%+33.33%+128.57%+79.76%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
International Stem Cell Co. stock logo
ISCO
International Stem Cell
-14.04%-14.04%-38.80%-24.54%-66.00%
Teligent, Inc. stock logo
TLGT
Teligent
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
1.5696 of 5 stars
3.53.00.00.02.30.80.0
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/A
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
3.00
Buy$16.00131.88% Upside
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/A

Current Analyst Ratings

Latest BNTC, INNVD, TLGT, BCTXF, and ISCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.00
2/15/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/A($4.55) per shareN/A
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$80K223.39N/AN/A$0.12 per share57.50
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
International Stem Cell Co. stock logo
ISCO
International Stem Cell
$7.79M0.07N/AN/A($0.57) per share-0.11
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
-$3.68M-$3.84N/AN/AN/AN/A-786.77%N/A
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
-$19.56MN/A0.00N/AN/A-204.34%-142.81%5/20/2024 (Estimated)
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
-$130K-$0.03N/AN/A-2.68%-2.80%-3.77%N/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest BNTC, INNVD, TLGT, BCTXF, and ISCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A-$0.04-$0.04-$0.04N/A$1.89 million
2/13/2024Q2 2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/A-$2.64-$2.64-$2.64N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/AN/A
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/A
0.07
0.07
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
0.01
3.62
3.62
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A
0.73
0.47
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
5772,000N/ANot Optionable
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
182.59 million2.48 millionNo Data
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
International Stem Cell Co. stock logo
ISCO
International Stem Cell
298.00 millionN/ANot Optionable
Teligent, Inc. stock logo
TLGT
Teligent
2,357N/AN/AOptionable

BNTC, INNVD, TLGT, BCTXF, and ISCO Headlines

SourceHeadline
Topical pain reliever recalled for problem that can cause ‘severe morbidity, even death’Topical pain reliever recalled for problem that can cause ‘severe morbidity, even death’
charlotteobserver.com - June 7 at 10:18 AM
β1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzzβ1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzz
news.google.com - May 13 at 1:32 AM
Lidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan NewsLidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan News
news.google.com - May 13 at 1:32 AM
Global Mobile Value-Added Services (VAS) Industry Market Report ... - Industry TodayGlobal Mobile Value-Added Services (VAS) Industry Market Report ... - Industry Today
news.google.com - May 11 at 4:41 AM
Global Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern ExaminerGlobal Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern Examiner
news.google.com - May 8 at 10:54 AM
Dry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPRDry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPR
news.google.com - May 8 at 5:54 AM
Mobile Value-Added Services (VAS) Market Size, Growth ... - Digital JournalMobile Value-Added Services (VAS) Market Size, Growth ... - Digital Journal
news.google.com - May 8 at 5:54 AM
Mobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern ExaminerMobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern Examiner
news.google.com - May 5 at 9:12 AM
Epinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital JournalEpinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital Journal
news.google.com - May 3 at 7:08 AM
Erythromycin Market with Focus on Growth Analysis, Production ... - Digital JournalErythromycin Market with Focus on Growth Analysis, Production ... - Digital Journal
news.google.com - May 2 at 8:42 AM
From 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital JournalFrom 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital Journal
news.google.com - April 29 at 8:17 AM
Tremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPRTremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPR
news.google.com - April 28 at 10:17 PM
Drugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPRDrugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPR
news.google.com - April 26 at 1:32 PM
Topical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPRTopical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPR
news.google.com - April 26 at 8:32 AM
Triamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan NewsTriamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan News
news.google.com - April 24 at 4:23 PM
IDT Corp. Cl BIDT Corp. Cl B
wsj.com - April 23 at 2:59 AM
Mobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital JournalMobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital Journal
news.google.com - April 17 at 2:17 PM
Hikma Names Injectables Chief Mishlawi As CEO - Generics BulletinHikma Names Injectables Chief Mishlawi As CEO - Generics Bulletin
news.google.com - April 12 at 1:13 PM
Mobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital JournalMobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital Journal
news.google.com - April 10 at 1:16 PM
Everstream Names Ken Fitzpatrick as President and Chief Executive ... - Joplin GlobeEverstream Names Ken Fitzpatrick as President and Chief Executive ... - Joplin Globe
news.google.com - April 6 at 1:58 PM
Lidocaine Ointment Market Growth Till, 2023-2030: Coherent Market ... - Digital JournalLidocaine Ointment Market Growth Till, 2023-2030: Coherent Market ... - Digital Journal
news.google.com - March 29 at 7:08 AM
Mobile Value-Added Services (VAS) Maket Is Set to Fly High in ... - Digital JournalMobile Value-Added Services (VAS) Maket Is Set to Fly High in ... - Digital Journal
news.google.com - March 29 at 2:07 AM
Gonorrhea Treatment Market Size 2023 - Current Sales Analysis, Upcoming Trends, Opportunities, Development His - openPRGonorrhea Treatment Market Size 2023 - Current Sales Analysis, Upcoming Trends, Opportunities, Development His - openPR
news.google.com - March 28 at 10:26 AM
Bankruptcy Standing: An Introduction to a Multitude | Reed Smith ... - JD SupraBankruptcy Standing: An Introduction to a Multitude | Reed Smith ... - JD Supra
news.google.com - March 25 at 8:59 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BriaCell Therapeutics logo

BriaCell Therapeutics

OTCMKTS:BCTXF
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Benitec Biopharma logo

Benitec Biopharma

NASDAQ:BNTC
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Innovus Pharmaceuticals logo

Innovus Pharmaceuticals

OTCMKTS:INNVD
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
International Stem Cell logo

International Stem Cell

OTCMKTS:ISCO
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.
Teligent logo

Teligent

NASDAQ:TLGT
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.